Evidence map›Paper›PMID 39493719›Full record

ArticleFrontiers in medicine2024

FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.

Lihong Wang, Lianhu Yu, Zhiyue Liu, Chao Che, Yu Wang, Yongheng Zhao, Mengna Zhu, Guang Yang, Aihua Cao

Abstract read
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Observational
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lihong Wang *Department of Pediatrics, Shandong University Qilu Hospital, Shandong, Jinan, China.
Lianhu Yu *Department of Pediatrics, Shandong University Qilu Hospital, Shandong, Jinan, China.
Zhiyue LiuDepartment of Pediatrics, Shandong University Qilu Hospital, Shandong, Jinan, China.
Chao CheDepartment of Pediatrics, Shandong University Qilu Hospital, Shandong, Jinan, China.
Yu WangDepartment of Pediatrics, Shandong University Qilu Hospital, Shandong, Jinan, China.
Yongheng ZhaoDepartment of Pediatrics, Shandong University Qilu Hospital, Shandong, Jinan, China.
Mengna ZhuDepartment of Pediatrics, Shandong University Qilu Hospital, Shandong, Jinan, China.
Guang YangDepartment of Pediatrics, Chinese PLA General Hospital, Beijing, China.
Aihua CaoDepartment of Pediatrics, Shandong University Qilu Hospital, Shandong, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Autism spectrum disorder (ASD) is often linked to gastrointestinal issues and altered serotonin metabolism. Emerging evidence suggests gut microbiota influence both, with fecal microbiota transplantation (FMT) offering a potential therapeutic approach. However, its impact on serotonin metabolism and ASD symptoms is not well understood. In this study, we aimed to evaluate the clinical effects of FMT and examine changes in specific urinary metabolites in children with ASD. Methods: A randomized double-blind controlled trial was performed to evaluate the clinical effects of FMT on GI and ASD-related symptoms. Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale (GSRS), and the ASD-related symptoms were assessed using the Childhood Autism Rating Scale (CARS), Aberrant Behavior Checklist (ABC), and Social Responsiveness Scale (SRS) scores. Urinary metabolites were analyzed by homogeneous enzyme immunoassay using commercially available kits. Results: Significant improvements in GI and core ASD symptoms were observed following FMT intervention. The average GSRS scores decreased from 30.17 (before) to 19 (after; Conclusion: FMT is a safe and effective treatment for improving GI and core symptoms in children with ASD, with 5-HIAA showing potential as a urinary biomarker for treatment response.

Indexed as

5-HT5-hydroxyindoleacetic acidautism spectrum disordersfecal microbiota transplantationurine metabolomics

Identifiers

PMID39493719
PMCPMC11529335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.